GlassScriptPhysician profile
Alok Bhargava
NPI 1114980968
$26,529.73
in general payments reported to CMS, 2019-2025
25 companies · $4,529 in 2025
The $4,529 reported for 2025 was more than what 85% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $633 · 2020: $1,222 · 2021: $7,566 · 2022: $5,262 · 2023: $3,407 · 2024: $3,910 · 2025: $4,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,384 · Food and Beverage: $3,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,384.00 |
| Food and Beverage | $3,462.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $20,575.52 | 2020-2025 | Valtoco |
| Tris Pharma INC | $1,537.85 | 2019-2025 | Dyanavel Xr, Onyda Xr, Quillichew Er |
| Ucb, INC. | $783.32 | 2019-2025 | Nayzilam, Briviact, Fintepla |
| Takeda Pharmaceuticals U.S.A., INC. | $534.84 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $515.54 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $448.87 | 2019-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $417.51 | 2019-2022 | |
| Corium, LLC | $382.01 | 2022-2025 | Azstarys |
| Eisai INC. | $255.04 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $196.00 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $181.34 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $146.52 | 2019-2025 | Relexxii |
| Acadia Pharmaceuticals INC | $98.78 | 2025 | Daybue |
| Alexion Pharmaceuticals, INC. | $86.06 | 2023-2025 | Koselugo |
| Adlon Therapeutics L.P. | $83.44 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $58.02 | 2019-2024 | |
| Aucta Pharmaceuticals, INC. | $40.56 | 2025 | Motpoly Xr |
| Rhodes Pharmaceuticals L.P. | $38.77 | 2019 | |
| Biomarin Pharmaceutical INC. | $31.90 | 2022-2024 | Brineura |
| Abbvie INC. | $27.86 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $21.73 | 2021 | |
| Alfasigma USA, INC. | $20.64 | 2021 | |
| Sk Life Science, INC. | $18.21 | 2020 | |
| Lundbeck LLC | $18.06 | 2020 | |
| Sumitomo Pharma America, INC. | $11.34 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alok Bhargava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.